Carmot Therapeutics

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.

Trana Discovery is a drug discovery technology company focused on developing new treatments for infectious diseases. The company offers a proprietary technology platform that assists partners in identifying potential drug candidates for bacterial, viral, and fungal infections. This technology is based on the inhibition of organism-specific transfer RNA (tRNA), which is crucial for the pathogen's propagation. It was founded in 2000 and is based in Cary, North Carolina.

InterveXion Therapeutics is a clinical-stage biotechnology company focused on developing therapies for methamphetamine use disorder. The company's main offerings include short and long-acting monoclonal antibodies and vaccines designed to bind methamphetamine and prevent its entry into the central nervous system. InterveXion primarily serves the healthcare sector, with a focus on addiction treatment and overdose management. It was founded in 2002 and is based in Little Rock, Arkansas.

Melior Discovery focuses on in vivo pharmacology and phenotypic screening within the biopharmaceutical industry. The company offers preclinical drug development services, including efficacy data collection, pharmacokinetic evaluations, and specialized animal model testing. Melior Discovery primarily serves the biopharmaceutical sector, providing tools and services for drug repositioning and indications discovery. It was founded in 2005 and is based in Exton, Pennsylvania.

Sequoia Sciences is a clinical-stage pharmaceutical company that operates in the healthcare industry. The company focuses on the discovery and development of novel vaccines to prevent bacterial infections, including recurrent urinary tract infections, and the treatment of certain cancers and lung infections associated with cystic fibrosis using small molecules. Its primary customer segments include the healthcare and pharmaceutical industries. It is based in St. Louis, Missouri.